Troriluzole (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Troriluzole" in English language version.

refsWebsite

Global rank English rank

4^th place

2^nd place

low place

low place

8,828^th place

102^nd place

76^th place

low place

doi.org

Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". Journal of Experimental Pharmacology. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J (July 2022). "A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research. 27 (1): 107. doi:10.1186/s40001-022-00732-w. PMC 9250196. PMID 35780243.
Pfitzer J, Pinky PD, Perman S, Redmon E, Cmelak L, Suppiramaniam V, Coric V, Qureshi IA, Gramlich MW, Reed MN (August 2024). "Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice". Journal of Neurochemistry. doi:10.1111/jnc.16215. PMID 39214859.

van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.

Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". Journal of Experimental Pharmacology. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI (January 2023). "Treatment-resistant OCD: Pharmacotherapies in adults". Comprehensive Psychiatry. 120: 152352. doi:10.1016/j.comppsych.2022.152352. hdl:2445/192315. PMID 36368186.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J (July 2022). "A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research. 27 (1): 107. doi:10.1186/s40001-022-00732-w. PMC 9250196. PMID 35780243.
Pfitzer J, Pinky PD, Perman S, Redmon E, Cmelak L, Suppiramaniam V, Coric V, Qureshi IA, Gramlich MW, Reed MN (August 2024). "Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice". Journal of Neurochemistry. doi:10.1111/jnc.16215. PMID 39214859.